$45.34
1.00% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US6047491013
Symbol
MIRM
Sector
Industry

Mirum Pharmaceuticals Inc Stock price

$45.34
+6.95 18.10% 1M
+1.65 3.78% 6M
+3.99 9.65% YTD
+20.04 79.21% 1Y
+19.76 77.25% 3Y
+28.17 164.07% 5Y
+32.13 243.22% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.45 1.00%
ISIN
US6047491013
Symbol
MIRM
Sector
Industry

Key metrics

Market capitalization $2.25b
Enterprise Value $2.29b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.03
P/S ratio (TTM) P/S ratio 5.92
P/B ratio (TTM) P/B ratio 9.61
Revenue growth (TTM) Revenue growth 69.31%
Revenue (TTM) Revenue $379.25m
EBIT (operating result TTM) EBIT $-76.32m
Free Cash Flow (TTM) Free Cash Flow $-7.87m
Cash position $277.67m
EPS (TTM) EPS $-1.61
P/E forward negative
P/S forward 5.03
EV/Sales forward 5.12
Short interest 12.59%
Show more

Is Mirum Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Mirum Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Mirum Pharmaceuticals Inc forecast:

10x Buy
100%

Analyst Opinions

10 Analysts have issued a Mirum Pharmaceuticals Inc forecast:

Buy
100%

Financial data from Mirum Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
379 379
69% 69%
100%
- Direct Costs 87 87
51% 51%
23%
292 292
76% 76%
77%
- Selling and Administrative Expenses 190 190
30% 30%
50%
- Research and Development Expense 154 154
39% 39%
41%
-52 -52
42% 42%
-14%
- Depreciation and Amortization 24 24
58% 58%
6%
EBIT (Operating Income) EBIT -76 -76
28% 28%
-20%
Net Profit -77 -77
50% 50%
-20%

In millions USD.

Don't miss a Thing! We will send you all news about Mirum Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mirum Pharmaceuticals Inc Stock News

Neutral
Business Wire
one day ago
FOSTER CITY, Calif.--(BUSINESS WIRE)---- $MIRM #leadership--Mirum Pharmaceuticals Appoints Doug Sheehy, JD as Chief Legal Officer.
Neutral
Business Wire
6 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences: 3rd Annual H.C. Wainwright BioConnect Investor Conference ...
Neutral
Business Wire
11 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
More Mirum Pharmaceuticals Inc News

Company Profile

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.

Head office United States
CEO Christopher Peetz
Employees 322
Founded 2018
Website www.mirumpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today